rivoceranib,camrelizumab,sorafenib
bayer,elevar therapeutics,jiangsu hengrui pharmaceuticals
['sorafenib', 'hcc', 'rivoceranib', 'camrelizumab']
results of a phase 3 study appear to indicate better progression-free and overall survival outcomes with camrelizumab and rivoceranib vs sorafenib in unresectable hepatocellular carcinoma. #hcc #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.